PURPOSE: Novel porous silicon microparticles were fabricated and loaded with fluorescein isothiocyanate (FITC)-insulin, a model hydrophilic pharmacologically active protein, along with varied doses of sodium laurate (C12), a well-known permeation enhancer. METHODS: Particle and liquid formulations were compared as a function of apical to basolateral flux of FITC-insulin across differentiated human intestinal Caco-2 cell monolayers grown on Transwell inserts. RESULTS: The flux of FITC-insulin from silicon particles across cell monolayers was nearly 10-fold higher compared with liquid formulations with permeation enhancer and approximately 50-fold compared with liquid formulations without enhancer. By increasing C12 dose per particle with a concomitant decrease in total particles added per monolayer, the percent of FITC-insulin transport resulted in a linear increase up to 25% monolayer coverage. CONCLUSIONS: Although maintaining monolayer integrity and transepithelial electrical resistance, maximum drug transport (20%/h) was achieved with 0.337 microg C12 dose per particle, and total particle loading at 25% monolayer coverage.
PURPOSE: Novel porous silicon microparticles were fabricated and loaded with fluorescein isothiocyanate (FITC)-insulin, a model hydrophilic pharmacologically active protein, along with varied doses of sodium laurate (C12), a well-known permeation enhancer. METHODS: Particle and liquid formulations were compared as a function of apical to basolateral flux of FITC-insulin across differentiated human intestinal Caco-2 cell monolayers grown on Transwell inserts. RESULTS: The flux of FITC-insulin from silicon particles across cell monolayers was nearly 10-fold higher compared with liquid formulations with permeation enhancer and approximately 50-fold compared with liquid formulations without enhancer. By increasing C12 dose per particle with a concomitant decrease in total particles added per monolayer, the percent of FITC-insulin transport resulted in a linear increase up to 25% monolayer coverage. CONCLUSIONS: Although maintaining monolayer integrity and transepithelial electrical resistance, maximum drug transport (20%/h) was achieved with 0.337 microg C12 dose per particle, and total particle loading at 25% monolayer coverage.
Authors: Shilpa Sant; Sarah L Tao; Omar Z Fisher; Qiaobing Xu; Nicholas A Peppas; Ali Khademhosseini Journal: Adv Drug Deliv Rev Date: 2011-12-04 Impact factor: 15.470
Authors: Jennifer S Park; Joseph M Kinsella; Danielle D Jandial; Stephen B Howell; Michael J Sailor Journal: Small Date: 2011-06-01 Impact factor: 13.281
Authors: Kathleen E Fischer; Aishwarya Jayagopal; Ganesh Nagaraj; R Hugh Daniels; Esther M Li; Matthew T Silvestrini; Tejal A Desai Journal: Nano Lett Date: 2011-01-31 Impact factor: 11.189
Authors: Takemi Tanaka; Lingegowda S Mangala; Pablo E Vivas-Mejia; René Nieves-Alicea; Aman P Mann; Edna Mora; Hee-Dong Han; Mian M K Shahzad; Xuewu Liu; Rohan Bhavane; Jianhua Gu; Jean R Fakhoury; Ciro Chiappini; Chunhua Lu; Koji Matsuo; Biana Godin; Rebecca L Stone; Alpa M Nick; Gabriel Lopez-Berestein; Anil K Sood; Mauro Ferrari Journal: Cancer Res Date: 2010-05-01 Impact factor: 12.701
Authors: Elizabeth C Wu; Jennifer S Andrew; Lingyun Cheng; William R Freeman; Lindsey Pearson; Michael J Sailor Journal: Biomaterials Date: 2010-11-30 Impact factor: 12.479